Latest Zoledronic acid Stories

2010-06-05 07:08:00

THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study").

2010-06-02 00:29:00

EAST HANOVER, N.J., June 2 /PRNewswire/ -- Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG, today announced that nearly 170 abstracts highlighting investigational uses of current therapies and investigational agents in the Novartis Oncology portfolio will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) from June 4 through June 8 in Chicago, IL (1).

2009-12-10 12:30:00

SAN ANTONIO, Dec. 10 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer.

2009-12-10 12:30:00

An estimated 70 to 80 percent of patients with advanced or stage four breast cancer develop bone metastases. Bone metastases occurs when the disease progresses to a patient's bones.

2009-10-23 06:50:00

US drug labels often omit key information about a medicine’s effectiveness and the severity of its side effects, according to a commentary written by two doctors in the New England Journal of Medicine.

Word of the Day
  • Of or relating to good digestion.
  • Cheerful.
The word 'eupeptic' comes from Greek roots meaning 'good' and 'digest'.